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ARTICLE
Escobar Syndrome Is a Prenatal Myasthenia Caused by Disruption
of the Acetylcholine Receptor Fetal g Subunit
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Christoph Hu¨bner, and Stefan Mundlos
Escobar syndrome is a form of arthrogryposis multiplex congenita and features joint contractures, pterygia, and respiratory
distress. Similar ﬁndings occur in newborns exposed to nicotinergic acetylcholine receptor (AChR) antibodies from
myasthenic mothers. We performed linkage studies in families with Escobar syndrome and identiﬁed eight mutations
within the g-subunit gene (CHRNG) of the AChR. Our functional studies show that g-subunit mutations prevent the
correct localization of the fetal AChR in human embryonic kidney–cell membranes and that the expression pattern in
prenatal mice corresponds to the human clinical phenotype. AChRs have ﬁve subunits. Two a, one b, and one d subunit
are always present. By switching g to  subunits in late fetal development, fetal AChRs are gradually replaced by adult
AChRs. Fetal and adult AChRs are essential for neuromuscular signal transduction. In addition, the fetal AChRs seem to
be the guide for the primary encounter of axon and muscle. Because of this important function in organogenesis, human
mutations in the g subunit were thought to be lethal, as they are in g-knockout mice. In contrast, many mutations in
other subunits have been found to be viable but cause postnatally persisting or beginning myasthenic syndromes. We
conclude that Escobar syndrome is an inherited fetal myasthenic disease that also affects neuromuscular organogenesis.
Because g expression is restricted to early development, patients have no myasthenic symptoms later in life. This is the
major difference from mutations in the other AChR subunits and the striking parallel to the symptoms found in neonates
with arthrogryposis when maternal AChR auto-antibodies crossed the placenta and caused the transient inactivation of
the AChR pathway.
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Escobar or multiple pterygia syndrome (MIM 609339 and
265000), a form of arthrogryposis multiplex congenita, is
an autosomal recessive condition characterized by exces-
sive webbing (pterygia), congenital contractures (arthro-
gryposis), and scoliosis.1,2 Variable other features include
intrauterine death, congenital respiratory distress, short
stature, faciocranial dysmorphism, ptosis, low-set ears,
arachnodactyly, and cryptorchism in males. Congenital
contractures are common and may be caused by reduced
fetal movements at sensitive times of development.3–5 Pos-
sible causes of decreased fetal mobility include space con-
straints such as oligohydramnion, drugs, metabolic con-
ditions, or neuromuscular disorders includingmyasthenia
gravis (MG [MIM 254200]).6 Myasthenia is characterized
by intermittent muscle weakness, most commonly caused
by autoantibodies binding to nicotinergic acetylcholine
receptor (AChR).7 During pregnancy, autoantibodies may
cross the placenta and cause transient muscle weakness
or, more seriously, an arthrogryposislike syndrome.8 He-
reditary causes of congenital myasthenic syndrome (e.g.,
MIM608931, 601462, 254210, and 608930]) have alsobeen
identiﬁed, mostly mutations in CHRNA1 (MIM 100690),
CHRNB1 (MIM 100710), CHRND (MIM 100720), and
CHRNE (MIM 100725), the genes encoding the a, b, d, and
 subunits of AChRs, respectively.9
The AChR is composed of ﬁve subunits; two a, one b,
and one d subunit are invariably present. The g subunit is
present before the 33rd wk of gestation in humans but is
replaced by an  subunit in the late fetal and perinatal pe-
riod, thereby forming the adult AChR (ﬁg. 1).10–13 The fetal
AChR helps to establish the primary encounter of muscle
and axon.14 Thus, the g subunit not only contributes to
neuromuscular signal transduction but is also important for
neuromuscular organogenesis. The importance of the fetal
AChR subtype for neuromuscular development is under-
scored by the lethal phenotype of g inactivation in mice.15
We identiﬁed CHRNG (MIM 100730) mutations in families
with Escobar syndrome and showed that the trait is a con-
genital dysmorphology caused by the transient inactivation
of the neuromuscular end plate.
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Figure 1. Structure and subunit composition of the fetal and adult AChR at muscle cells. Acetylcholine release from nerve terminals
results in activation of the AChR at the postsynaptic membrane. This triggers an end-plate potential that activates voltage-dependent
sodium channels and ﬁnally generates an action potential in the muscle. An AChR consists of a pentamer of paralogous subunits. Two
types of skeletal-muscle AChR are identiﬁed by their different functions and subunit compositions. A, Fetal AChR. A fetal type of AChR
has 2a, b, g, and d subunits and is synthesized before week 33 of gestation in humans and before postnatal day P9 in mice.10–12 B,
Adult AChR. Adult-type AChRs are formed through a gradual replacement of the fetal g by the adult  subunit.12,13
Table 1. CHRNG Mutations in Escobar Syndrome
Characteristic
Findings for g Subunit of AChR by Family and Mutation
EG-1 EG-2 EG-3 EG-4 EG-5 EG-6 EG-7
Location (exon) 1 8 4 and 5 4 and 12 10 7 7
Position cDNA 13CrTa 807insTa 256CrT/481GrA 300dup(9)/1408CrT 1249GrCa 715CrTa 715CrTa
Residue in mature proteinb g Q-18X g D248–274, 275X g R64C/g W139X g 78dup(3)/g R448X g D395–418,419Xc g R217C g R217C
Family data:
Origin Oman Lebanon Switzerland Germany Lebanon Lebanon Turkey
Consanguinity       
Family history of abortions NA      
NOTE.—EG p Escobar syndrome by CHRNG mutation; NA p not available.
a Homozygous.
b After cleavage of signal peptide.
c Or g E395Q.
Methods
Patients
We studied seven families with Escobar syndrome and control
individuals. The families came from Germany, Lebanon (three
families), Oman, Switzerland, and Turkey (table 1 and ﬁg. 2). Five
families were consanguineous. Our ethics committee approved
the study, and written, informed consent was obtained from all
participants or their legal guardians. Patients did not give consent
to a muscle biopsy for scientiﬁc purposes.
Genomewide Scan, Fine Mapping, and Sequencing
We used the 10K Affymetrix SNP chip for our genome scan
and analyzed the data using ALLEGRO v1.2c,16 GENEHUNTER
v2.1r5,17 and easyLINKAGE v5.03.18 We assumed a recessive model
with complete penetrance, 0.001 disease-allele frequency, and
equally distributed marker-allele frequencies. Fine mapping with
microsatellites was done as described elsewhere.19 We included
all available family members and additional families, and we re-
constructed haplotypes by GENEHUNTER andmanually.Wenext
sequenced functional candidate genes within the linkage interval
with standard sequencing procedures.19 Primer sequences are
available on request. All described CHRNG mutations were tested
in control chromosomes and for correct segregation within the
patients’ families.
Human Embryonic Kidney (HEK) Cell–Expression Studies
We cloned ampliﬁed cDNA sequences of wild-type and mutant
mouse AChR subunits into the expression vector system pRC/
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Figure 2. Pedigrees of families with Escobar syndrome caused by CHRNG mutations
CMV2 (Invitrogen). The human mutations 78dup(3), R217C, and
R448X were introduced into the wild-type g AChR vector by PCR-
based mutagenesis. Since the mouse cytoplasmic loop of the g
subunit is 2 aa longer than the human form, human amino acid
R448 corresponds to R450 in mice.
HEK293 cells were grown at 37C on uncoated glass cover slips
in Dulbecco’s modiﬁed Eagle medium supplemented with 10%
fetal bovine serum; 24 h after plating, we transfected cells with
a, b, d, and either wild-type ormutant g subunit vector constructs,
at a ratio of 2:1:1:1, with 5 mg as the amount of a subunit plas-
mid. Forty-eight hours after transfection, cells were rinsed with
PBS and were ﬁxed with 4% paraformaldehyde. To visualize ex-
pression of AChR, we then incubated with 2 mg/ml a-bungaro-
toxin and Alexa Fluor 594 conjugate (Invitrogen), for 1 h at room
temperature. After rinsing with PBS, cells were mounted on spec-
imen supports (DAKO Fluorescent Mounting Medium) and were
analyzed by ﬂuorescence microscopy with use of a Leica DM RBE
microscope.
Section In Situ Hybridization
We prepared mouse embryos of stages of embryonic day 14.5
(E14.5), cut frozen 15-mm sections, and used the semi-automated
TECAN GenePaint system.20 Probes for AChR subunits were gen-
erated by RT-PCR from mouse E14.5 whole cDNA (g) and P9
whole hindlimb cDNA (). Antisense riboprobes were transcribed
with T7 polymerase with the Roche Dig-RNA labeling kit accord-
ing to the manufacturer’s instructions. For each subunit, we gen-
erated two independent probes, hybridizing to different portions
of the RNA to verify speciﬁcity of the signal. Primer sequences
are available on request.
Results
We studied seven families that had children with Escobar
syndrome (tables 1 and 2 and ﬁg. 2). All patients had
clinical features consistent with arthrogryposis multi-
plex congenita and multiple pterygia (ﬁg. 3A–3C) and pre-
sented faciocranial dysmorphism, short stature, and crypt-
orchism in male. Scoliosis, arachnodactyly, facial weak-
ness, and respiratory distress were variably expressed (ﬁg.
3D–3E). Most patients had high-arched palate and low-set
ears. Family history of reduced prenatal movement and/
or spontaneous abortions was frequently reported. All sur-
viving patients had growth retardation but normalmental
development. Interestingly, features of myasthenia were
absent. Electromyography (EMG) in patient II-2 of family
EG-4 did not reveal spontaneous activity while at rest.
Early recruitment of low-amplitude and polyphasic mus-
cle action potentials were noted.Motor nerve–conduction
velocity and distal latency of the right median nerve (56
m/s, 1.8 ms) and sensory nerve–conduction velocity and
amplitude of the right median nerve (66m/s, 31mV) were
normal. Repetitive stimulation of the right median nerve
with 3 Hz did not reveal a pathological decrement. Thus,
there was no sign of a neuromuscular transmission defect
in this patient, but there was some indication ofmyogenic
lesion by electrophysiological standards. Similar results
were obtained for families EG-1, EG-2, and EG-6.
Testing of pulmonary function in patient II-2 of family
EG-4 at age 18 years revealed a severely reduced vital ca-
pacity (0.7 liter, corresponding to 27% of age-, sex-, and
height-matched normal value); cardiac function was nor-
mal on echocardiography. Cardiac and pulmonary func-
tion tests were not available for the other families. How-
ever, two patients (patients II-1 in family EG-3 and II-1 in
family EG-4) showed congenital eventration of the dia-
phragm on chest x-ray, indicating diaphragmatic muscle
weakness. One (from family EG-3) also had congenital
pulmonary hypoplasia.
We found a region with signiﬁcant linkage to chro-
mosome 2q37 (multipoint parametric LOD score 3.26) in
family 1, described elsewhere by Rajab et al.2 Subsequent
microsatellite analyses revealed a LOD score of 3.51. We
conﬁrmed that region in another consanguineous family,
EG-1, with two affected and eight unaffected offspring
( ). Fine mapping and haplotyping narrowedLODp 3.25
Table 2. Clinical Features in Patients with Escobar Syndrome
Characteristic
Findings for Escobar Syndrome by Individuala
EG-1 II-3 EG-1 II-5 EG-2 V-1 EG-2 V-2 EG-3 II-1 EG-4 II-1 EG-4 II-2 EG-5 V-1 EG-5 V-4 EG-6 IV-3 EG-6 IV-5 EG-7 II-1
Sex F M F M F M M M F F F F
Current ageb 12 5 21 16 Died at age 3 mo Died at age 3 mo 18 14 7 Died at age 13 d 7 Stillborn
Congenital problems:
Decreased movements NA NA NA         Stillborn
Facial weakness      NA    NA  Stillborn
Respiratory distress            Stillborn
Dysmorphic signs:
Arthrogryposis multiplex            
Pterygia          NA  
Short stature      NA    NA  NA
Kyphosis/scoliosis          NA  NA
Faciocranial dysmorphism      NA      NA
High-arched palate      NA    NA  NA
Cleft palate      NA      NA
Arachnodactyly            NA
Cryptorchism …  …  …    … … … …
Postnatal myasthenic features:
Clinical myasthenic symptoms      NA    NA  Stillborn
Myasthenic signs on EMG    NA NA NA  NA NA NA  Stillborn
NOTE.—The ﬁrst sign diagnosed by ultrasound or reported by mothers is reduced fetal movement. At birth, the children come to medical attention because of variable joint contractures,
multiple pterygia, and facial dysmorphism with long face, high-arched palate, small mouth, and retrognathism. Respiratory distress is a frequent life-threatening complication. Later in
life, patients frequently are affected by reduced muscular mass but do not show myasthenic symptoms and have normal EMG, except for unspeciﬁc indication of chronic myopathy. The
phenotype can vary between mutations and also within one class of mutations. NA p not available.
a EG p Escobar syndrome by CHRNG mutation.
b In years, unless otherwise speciﬁed.
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Figure 3. Clinical phenotype of patients with Escobar syndrome. The consistent major signs of Escobar syndrome are multiple con-
tractures (arthrogryposis) and multiple pterygia. We show hand contractures (A), rocker-bottom feet with prominent heels (B), and an
elbow web with muscular atrophy (C). The phenotype is variable, as shown for two patients from different families. Patient IV-5, from
family EG-6, with homozygous mutation gR217C is more severely affected (D) than patient V-1, from family EG-5, with homozygous
mutation g1249GrC (E). The general appearance—with elongated face, small mouth with downturned corners, mild ptosis, down-
slanting palpebral ﬁssures, multiple pterygia, and muscular hypotrophy—is present in both patients. Scoliosis is severe in one patient
(D) and absent in the other (E).
the region to a 10-cM interval between markers D2S172
and D2S336 (235.07–245.44 cM, according to Marshﬁeld
genetic maps).
Within that region resides the gene encoding the fetally
expressed g subunit of the AChR. Results of mutation
screening are given in ﬁgure 4 and table 1. We iden-
tiﬁed three nonsense (gQ-18X, gW139X, and gR448X),
one putative splice-site (g1249GrC), and one frameshift
(g807insT) mutation in CHRNG. These mutations are pre-
dicted to truncate major parts of the g subunit or to result
in premature mRNA nonsense-mediated decay. Mutations
gR64C, gR217C, and g78dup(3) affect evolutionaryhighly
conserved residues, indicating functional relevance (ﬁg.
5). The mutations cosegregated with the phenotype in the
families and were not found in 292 control chromosomes,
thus making a polymorphism unlikely. In two other fam-
ilies, including the family of the initial genomewide scan,
we did not identify mutations, either within the coding
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Figure 4. Schematic structure of the AChR g subunit and local-
ization of the identiﬁed mutations. The g subunit and the other
subunits contain an extracellular large N-terminus where acetyl-
choline binds and drugs and toxins dock (nicotine, muscle relax-
ants, D-tubocurarine, and a-bungarotoxin). Then, four transmem-
brane domains (M1–M4) follow with a large cytoplasmic domain
(CD2) between M3 and M4 and an extracellular short C-ter-
minus.21,22 Subunit structure was adapted from the work of Engel
and Sine.9 The g subunit consists of 517 aa, starting with the
start methionine. Residues were counted, in accordance with tra-
ditional nomenclature, from the ﬁrst amino acid following the
signal peptide. S-S marks an important cysteine loop.
part and introns of CHRNG or in the 5′ and 3′ UTRs. We
assume that, for these families, the disease-causing mu-
tation likely affects a regulatory element farther apart from
the 5′ and 3′ end of CHRNG, is due to a cytogenetic re-
arrangement affecting CHRNG expression, or is due to a
mutation in another gene within the linked region. We
excluded the coding part of CHRND that is located within
the linked region.
We transfected HEK cells with expression vectors for
a, b, g, and d subunits that resembled the wild-type sit-
uation in the developing fetus. This resulted in regular
AChR assembly and positioning at the cellular surface (ﬁg.
6A). In contrast, without the g subunit–expression vector,
the complex made by all other subunits did not move to
the cell surface, since there was no cell surface bungaro-
toxin-staining (ﬁg. 6I). This state of affairs corresponds to
the gQ-18X mutation. Introduction of the mutations
g78dup(3), gR217C, or gR448X into the g-expression vec-
tor also prevented AChR positioning at the cellular surface
(ﬁg. 6C, 6E, and 6G, respectively). The muscle-type nic-
otinic AChR subunits assemble into functional a2-b-g-d
pentamers in the endoplasmic reticulum (ER) through a
series of folding and oligomerization events.21 Assembly
intermediates can be detected in the ER of transfected cells
as soon as one of the bungarotoxin-binding sites forms—
for example, a-d dimers. This is the case also in cells trans-
fected with wild-type a, b, d, andmutant g subunits,where
a staining of the ER by bungarotoxin was achieved when
cells were permeabilized (ﬁg. 6D, 6F, 6H, and 6J). In sum-
mary, we see in the tested g mutations that there is a
partial subunit assembly in the ER but noAChR expression
at the cellular surface.
To illustrate the AChR expression at a time putatively
sensitive to the development of arthrogryposis in embryo-
genesis, we studied the expression of the g and  subunits
in mouse embryos at E14, in limb sections at E15, and in
limb muscle sections at postnatal days P1, P4, and P7. As
expected, the  subunit was not expressed before birth
(data not shown). At E14, robust g expression was ob-
served in limb, paravertebral, facial, intercostal, and neck
musculature and in the diaphragm (ﬁg. 7A). Individual
muscle-ﬁber staining is shown for E15 (ﬁg. 7B and 7C).
No expression was detected in the heart or the intestine.
Postnatally, the expression of the g subunit was strong
and focal on P1 (ﬁg. 7D) and P4 (not shown) but decreased
by P7 (ﬁg. 7E). The  subunit was not visible on P1 (ﬁg.
7F), was visible on P4, and was robustly expressed on P7
(ﬁg. 7G), supporting earlier data.11
Discussion
Mutations in the genes encoding the a (CHRNA1), b
(CHRNB1), d (CHRND), and  (CHRNE) AChR subunits
cause congenital myasthenic syndrome.9 In contrast, pa-
tients with Escobar syndrome have normal muscle tone
and no myasthenic symptoms later in life. We present
compelling evidence that CHRNG mutations are respon-
sible for the arthrogryposis multiplex congenita observed
in Escobar syndrome. Themutations result in an impaired,
truncated, or absent g subunit. We show that fetal AChR
cannot be expressed on the surface of HEK cells when the
g subunit is mutated or missing. We also demonstrate that
the g subunit is expressed at sites and at a time in fetal
life corresponding to the development of the clinical phe-
notype. Impaired g-subunit structure results in improper
AChR function in fetal life, with reduced prenatal muscle
strength and movement. This explains dysmorphic con-
sequences such as contractures, pterygia, high-arched pal-
ate, and cryptorchism in male. Since the g subunit gen-
erally disappears in late fetal development and is replaced
by the  subunit, the patients exhibit almost no progres-
sion and no signs of myasthenia after birth.
The ﬁve AChR subunits have to be fully assembled in
the ER before the receptor is inserted into the mem-
brane.21,25 If one subunit is missing, the receptor cannot
reach the cell surface, which results in AChR deﬁciency,
as shown for nonsense and some missense mutations in
the  subunit.9 The g nonsense mutations described here
are expected to have similar effects. This hypothesis is
supported by our in vitro experiments showing lack of
fetal AChR at the cell surface in the absence of the g sub-
unit. The expression studies in transfected HEK cells indi-
cate that the mutations g78dup(3), gR217C, and gR448X
lead to AChR deﬁciency at the cell surface as well. The
pathogenic effect of these mutations results from either
Figure 5. Evolutionary conservation of residues relevant for identiﬁed missense and duplication mutations. A, Evolutionary conservation
of residue gR64 relevant for mutation gR64C. The strongly basic residue arginine R is conserved in human b, d, g, and  subunits, as
well as among vertebrate g subunits. Furthermore, insertion of an additional cysteine residue instead of arginine might interfere with
the cysteine loops relevant in and between AChR subunits. B, Evolutionary conservation of residues relevant for mutation g78dup(3).
The duplication of residues WVL is located before an R that is evolutionarily completely conserved among g subunits of all species
analyzed and close to a conserved W_PDI_L-motif. The analogous position in the  subunit L78 was shown to locate at the interface
of a and  subunits in snail AChR and seems to provide a hydrogen bond between the b sheets involved in acetylcholine binding.23,24 C,
Evolutionary conservation of residue gR217 relevant for mutation gR217C. Residue gR217 is completely conserved in all human subunits
as well as within all species analyzed. Furthermore, insertion of an additional cysteine residue instead of arginine might interfere with
the cysteine loops relevant in and between AChR subunits. The line marked “M1” depicts the beginning of the transmembrane domain
M1. GenBank accession numbers for alignment of human AChR subunits are as follows: NP_000070.1 (CHRNA1), NP_000738.2 (CHRNB1),
NP_000742.1 (CHRND), NP_000071.1 (CHRNE), and NP_005190.4 (CHRNG). GenBank accession numbers for interspecies comparison of
g subunit homologs are as follows: NP_005190.4 (Homo sapiens), P13536 (Bos taurus), P04760 (Musmusculus), P18916 (Rattusnorvegicus),
P02713 (Gallus gallus), P05376 (Xenopus laevis), P02714 (Torpedo californica), Q4RV81 (Tetraodon nigroviridis), Q7T2Y7 (Fugu rubripes),
F09E8.7* (Caenorhabditis elegans), and P04755* (Drosophila melanogaster). The Ensembl number is ENSDART00000028118** (Danio rerio).
(Those in the ﬁgure marked with an asterisk [*] are the closest homologs to the human CHRNG found in D. melanogaster and C. elegans,
respectively.)
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Figure 6. AChR expression. Altered or missing g subunit prevents
surface expression of fetal AChRs in HEK-cell studies. Transfection
with the a, b, g, and d subunits results in regular assembly and
positioning of the fetal AChR at the cellular surface (A). No AChR
surface expression is seen when the g transfection vector carries
mutations g78dup(3) (C), gR217C (E), or gR448X (G) or is com-
pletely missing (I). There might be a partial AChR subunit assembly
within the cell, since after-permeabilization bungarotoxin stains
the ER (D, F, H, and J). (Receptors were visualized with bungaro-
toxin staining.)
Figure 7. In situ hybridization. In situ hybridization at mouse
E14.5 shows a signiﬁcant expression of the g subunit in skeletal
muscles of the limbs, neck, and head, paravertebrally as well as
in the diaphragm (A–C). This corresponds to the major sites of the
phenotype observed in human Escobar syndrome. Postnatally, the
g subunit expression decreases (D and E), with reciprocal increase
of the  subunit (F and G). EOM p Extraocular muscles; ICM p
intercostal muscles; PVT p paravertebral trunk.
severely reduced expression levels of the mutated g sub-
units or from impaired AChR assembly or transport.
Although all patients consistently showed arthrogry-
posis multiplex and multiple pterygia, severity of the clin-
ical phenotype varied signiﬁcantly among and within
families. For example, homozygous mutation gR217Cwas
associated with an affected stillbirth in family EG-7 as well
as with neonatal death and a viable though severe phe-
notype in two patients from family EG-6. We also suspect
that this homozygous mutation caused the history of
abortions in these families. In family EG-4, one affected
boy died at age 3 mo, and his 18-year-old brother is se-
verely affected. Therefore, not only the status of the mu-
tations but also genetic background and interindividual
differences at the time of the g- switch might be of
relevance.
In situ hybridization at mouse E14 showed that the g
subunit is expressed in skeletal muscles of the limbs, head,
paravertebral trunk, and in the diaphragm. This pattern
corresponds to the major sites of human disease. Post-
natally, g expression decreased along with a reciprocal in-
crease in the  subunit, indicating that the disease is
mainly relevant for intrauterine neuromuscular develop-
ment. We conclude that the observed postnatal symp-
toms—namely arthrogryposis, pterygia, and scoliosis—are
a result of improper AChR function in utero. There is little
or no progression of the disease after birth, although the
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deformities may nevertheless lead to lethal complications.
This phenomenon explains the lack of myasthenia in pa-
tients with g mutations after birth. Accordingly, lack of
the g subunit inmice causedmuscularweakness, hindlimb
paralysis, feeding problems, and stillbirth and death
within 48 h because of respiratory failure.15 Homozygous
-knockout mice showed normal development in prenatal
and early neonatal life but later developed progressive im-
pairment of neuromuscular transmission with muscular
weakness and death around age 2–3 mo.26,27 The late onset
and rather mild phenotype are due to inadequate but
partly compensatory g expression postnatally.27 In con-
trast, no compensatory increase of  expression was ob-
served in mice lacking the g subunit, resulting in a near
absence of AChR in muscle ﬁbers.15
We found that individuals with CHRNG nonsense mu-
tations can survive, although an increased frequency of
stillbirth and abortions is noted in their families. In con-
trast to the postnatal switch in mice, expression of the 
subunit starts already prenatally at ∼7 mo of pregnancy
in the bovine diaphragm and ∼33 wk of gestation in
humans.13,10 The subunit switch in early postpartal time
in mice and in late gestation in humans indicates that
mice might be born with fetal AChR, whereas humans
and cows already have adult AChR. A prenatal start of 
expression, especially in respiratory muscles, might be the
life-saving difference.
Antibodies in myasthenia gravis could be directed
against any subunit. However, there is some evidence that
women whose babies are affected by maternal AChR an-
tibody–induced myasthenia have higher titers of antibod-
ies and a higher proportion that bind to fetal AChR epi-
topes.8 These women can be asymptomatic, but their
children are affected with severe arthrogryposis and hy-
potonia.28–32 Almost all features—such as decreased fetal
and congenital movements, arthrogryposis, facial weak-
ness, respiratory distress, pulmonary hypoplasia, kypho-
sis/scoliosis, intrauterine growth retardation, faciocranial
dysmorphism, low-set ears, high-arched palate, and crypt-
orchism—we have seen in our patients were also reported
in stillbirths or newborns after intrauterine exposure to
fetal AChR antibodies.29–32 Pathogenicity of these antibod-
ies was also demonstrated by exposing rodents to human
maternal AChR antibodies. Most rodent pups showedmul-
tiple contractures, craniofacial dysmorphism, and multi-
ple pterygia, similar to the human phenotype.8 Fetal ex-
posure to D-tubocurarine blocks fetal AChR and results
in arthrogryposis multiplex congenita and pterygia.4,33–35
Taken together, features seen in our patients with CHRNG
mutations are mimicked by drug or antibody inhibition
of the fetal AChR.
In our patients, CHRNG mutations are frequently as-
sociated with congenital diaphragmatic muscle weakness,
pulmonary hypoplasia, or respiratory distress. This might
suggest that g-subunit alterations can lead to respiratory
dysfunction, probably by both decreased muscle move-
ment and disturbed lung development. This is supported
by a case report in which intrauterine exposure to fetal
AChR antibodies led to pulmonary hypoplasia and mal-
segmentation of pulmonary lobes.32
We identiﬁed functional null mutations in the g subunit
of AChR in Escobar syndrome that presumably result in
the inability to assemble the receptor and thus the down-
regulation of the entire fetal AChR complex. We conclude
that Escobar syndrome is an inherited fetal myasthenic
disease that also affects neuromuscular organogenesis. Be-
cause g expression is restricted to early development, pa-
tients have no myasthenic symptoms later in life, in con-
trast to those with mutations in other AChR subunits. Our
ﬁndings are of relevance not only for the rare inherited
Escobar syndrome but also for other fetal akinesia/hypo-
kinesia sequences, congenital myasthenic syndrome, and
myasthenia gravis. They also support the pathogenetic
views of arthrogryposis and pterygia in general and the
complex regulation and function of AChR subunits during
and after development. We think that Escobar syndrome
elucidates the missing link among inherited AChR-sub-
unit disorders and appears to be a phenocopy of the most
severe form of neonatal myasthenia gravis.
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